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Abstract
Background: It has recently been hypothesized that hyperglutamatergia in the brain is involved in the pathophysiology of
autism. However, there is no conclusive evidence of the validity of this hypothesis. As peripheral glutamate/glutamine levels
have been reported to be correlated with those of the central nervous system, the authors examined whether the levels of
25 amino acids, including glutamate and glutamine, in the platelet-poor plasma of drug-naı ¨ve, male children with high-
functioning autism (HFA) would be altered compared with those of normal controls.
Methodology/Principal Findings: Plasma levels of 25 amino acids in male children (N=23) with HFA and normally
developed healthy male controls (N=22) were determined using high-performance liquid chromatography. Multiple testing
was allowed for in the analyses. Compared with the normal control group, the HFA group had higher levels of plasma
glutamate and lower levels of plasma glutamine. No significant group difference was found in the remaining 23 amino
acids. The effect size (Cohen’s d) for glutamate and glutamine was large: 1.13 and 1.36, respectively. Using discriminant
analysis with logistic regression, the two values of plasma glutamate and glutamine were shown to well-differentiate the
HFA group from the control group; the rate of correct classification was 91%.
Conclusions/Significance: The present study suggests that plasma glutamate and glutamine levels can serve as a
diagnostic tool for the early detection of autism, especially normal IQ autism. These findings indicate that glutamatergic
abnormalities in the brain may be associated with the pathobiology of autism.
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Introduction
Autism is a neurodevelopmental disorder that affects 1–2 in 100
children, according to recent data on the broad array of autism
spectrum disorders (ASD) [1]. The disorder is characterized by
severe and sustained impairment of social interaction, abnormal-
ities in communication, and patterns of repetitive behaviors and
restricted interest [2]. Although genetic predisposition and
environmental contributors have been implicated in the patho-
physiology of autism, the precise mechanisms underlying the
pathophysiology of this disorder remain unknown [3] and there
are no established methods of prevention or cure. Receiving
diagnosis at an early stage of development could contribute to the
acquisition of optimized coping strategies for both patients and
their families. However, while diagnosis of autism is based solely
on behavioral abnormalities, such abnormalities are often
overlooked in early life, even among professionals involved in
pediatric healthcare [4]. Therefore, it remains necessary to
establish a reliable hallmark that could contribute to an early
and more precise autism diagnosis.
Glutamate, the major excitatory neurotransmitter, is highly
concentrated throughout the brain and is crucial to neuronal
plasticity and the maintenance of cognitive functioning. However,
excess glutamate has been shown to be a potent neurotoxin that
leads to neuronal cell death [5,6] and is deemed to play a role in
the pathophysiology of some neuropsychiatric disorders [7].
Recently, a hyperglutamatergic hypothesis of autism was proposed
[8,9] based on evidence of hyperglutamatergia in the brain of
individuals with autism. For instance, Fatemi et al. [10] have
shown that levels of GAD 65 kDa and GAD 67 kDa proteins,
both of which are involved in converting glutamate to GABA, are
reduced in the brains of individuals with autism, resulting in
increased levels of glutamate in the brain substrate. In addition, a
neuroimaging magnetic resonance spectroscopy study by Page et
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25340al. (2006) has demonstrated that individuals with ASD have
significantly higher concentrations of glutamate in the amygdala-
hippocampal region than do healthy controls [11].
Although glutamate is thought not to readily cross the blood
brain barrier [7], the level of glutamate in the blood is positively
correlated with the cerebrospinal fluid (CSF) level of glutamate in
humans [12,13]. In fact, increased plasma levels of glutamate have
been reported in some neuropsychiatric disorders, such as epilepsy
[14], Alzheimer’s disease [15] and amyotrophic lateral sclerosis
[16], in which glutamate excitotoxicity is thought to play a role in
the pathophysiology. Thus, the peripheral glutamate level can be
postulated to reflect the glutamate level in the brain per se. In our
previous study, we found that the serum level of glutamate was
significantly higher in young adults with autism than in adult
controls [17], suggesting that individuals with this condition may
have a high concentration of glutamate in the brain. However, the
results reported in the literature are contradictory, with some
studies showing no association between serum glutamate and
autism [18,19]. Such inconsistencies could be due to differences
among the samples studied. In fact, there has been considerable
variation among the previous studies [17,18,19,20] in terms of age,
gender, IQ, and use of psychoactive medication, as well as in the
methods of blood sample collection (e.g., serum, platelet-rich
plasma, or platelet-poor plasma).
Because autism is a heterogeneous disorder [21], the selection of
study samples is likely to affect the results. In order to make our
study sample as homogeneous as possible and to render the
findings easily interpretable (and comparable), we limited the
inclusion of subjects to drug-naı ¨ve, male children with high-
functioning autism (HFA), and we chose platelet-poor plasma for
the blood sample collection. The rationale for these choices was as
follows. First, the findings of a sample of adults may merely reflect
glutamate levels related to the duration of illness, and may
therefore represent secondary changes in response to some
compensatory process. Therefore, it is preferable to examine a
sample of children with the disorder, since children are less likely
to be influenced by the disease duration. Second, it is well
documented that 40–62% of individuals with autism have some
intellectual impairment [22]. Controlling for the Intelligence
Quotient (IQ) or excluding those individuals with autism who have
intellectual disabilities could eliminate factors that are related to
general intellectual impairments but unrelated to autism. Third,
because sex differences in autism have been reported [23,24,25],
we chose to examine only male subjects, among whom autism is
more prevalent. Fourth, since neurotransmitter systems are
extremely sensitive to psychoactive medications, we recruited only
drug-naı ¨ve individuals with HFA. Finally, some amino acids, such
as glutamate and glutamine, are contained in blood platelets [26];
thus, when amino acids are examined in peripheral blood, platelet-
poor plasma samples could yield more informative data than
serum samples.
We therefore performed a high-performance liquid chromatog-
raphy (HPLC) analysis of glutamate levels in the platelet-poor
plasma of drug-naı ¨ve, male children with HFA. Since amino acids
exert various influences on one another in the process of amino
acid synthesis/degradation, any changes in plasma glutamate
levels could be attributed to changes in other amino acids or in
related compounds such as urea and taurine. Therefore, we
comprehensively analyzed a total of 41 amino acids and amino
acid-related compounds (for brevity, hereafter amino acids),
including glutamate, in the plasma of male, drug-naı ¨ve children
with autism. As the levels of 16 amino acids (see Materials and
Methods below) were found to be undetectable by HPLC, we
ultimately investigated the plasma levels of only 25 amino acids
(see Table 1) in the individuals with autism and healthy controls.
We hypothesized that plasma levels of glutamate, but not those of
other amino acids, would be elevated in children with autism
relative to those of healthy children.
Results
There was no significant difference in age (t=1.79, df=43,
p=0.081), IQ (t=22.00, df=43, p=0.052), BMI (body-mass
index; t=1.06, df=43, p=0.29), or plasma creatinine levels
(t=0.99, df=43, p=0.33) between the HFA and control groups
(Table 2). Although non-significant, the marginal difference in age
and IQ could not be overlooked, and was taken into account in
subsequent analyses. The plasma levels of 25 amino acids were
analyzed using HPLC, and are shown in Table 1. There were no
significant intergroup differences in the amino acid plasma levels,
with the exception of glutamate and glutamine (Table 1). Only the
results for these two amino acids, i.e., glutamate and glutamine,
met the criterion for statistical significance. As anticipated, the
plasma level of glutamate was significantly higher in the HFA
group (mean 6 S.D.=27.967.4 mM) than in the control group
(mean 6 S.D.=20.964.5 mM) (t=3.77, df=43, p,0.002)
Table 1. Plasma Levels of Amino Acids and related
compounds in Control Subjects and Individuals with HFA.
Amino acid Control HFA p-value
Alanine 326.1661.6 300.3655.0 0.145
a-Aminobutyric acid 18.863.8 18.765.4 0.971
Arginine 89.1619.0 95.3618.5 0.279
Asparagine 40.868.3 43.167.0 0.311
Citrulline 29.266.1 29.164.7 0.934
Cysteine 21.963.7 22.563.6 0.586
Glutamate 20.964.5 27.967.4 ,0.002*
Glutamine 513.1648.5 445.8650.6 ,0.0004**
Glycine 220.4632.2 202.7642.9 0.127
Histidine 73.166.4 76.667.9 0.120
Hydroxyproline 20.562.2 22.563.6 0.097
Isoleucine 53.6611.5 62.2614.5 0.033
Leucine 99.0616.1 106.4622.4 0.210
Lysine 155.3628.5 164.2632.5 0.332
Methionine 23.765.1 25.865.6 0.203
Ornithine 43.9611.3 51.9610.8 0.021
Phenylalanine 51.766.8 55.168.4 0.146
Proline 153.7656.4 131.7647.6 0.165
Serine 105.4615.6 115.8614.7 0.027
Taurine 33.465.5 37.867.9 0.036
Threonine 100.8619.7 112.0624.3 0.097
Tryptophan 44.865.6 47.366.4 0.167
Tyrosine 60.9610.5 58.4610.1 0.425
Urea 3976.36818.7 3759.96773.3 0.367
Valine 200.2629.4 217.1629.7 0.062
HFA: High-Functioning Autism.
Values are expressed as the mean 6 SD.
Two-tailed unpaired t-test with the Bonferroni correction,
*p,0.002,
**p,0.0004.
doi:10.1371/journal.pone.0025340.t001
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interval [CI]: 3.3 to 10.7 mM), with a Cohen’s d of 1.13. In
contrast, the plasma level of glutamine in individuals with HFA
(mean 6 S.D.=445.8650.6 mM) was significantly lower than that
of normal controls (mean 6 S.D.=513.1648.5 mM) (t=24.55,
df=43, p,0.0004) (Fig. 1b); the mean difference was 267.3 mM
(95% CI: 297.2 to 237.5 mM), with an effect size of 1.36.
Since marginal differences in age and IQ were noted between
the two groups, ANCOVA was used to adjust for these factors.
When the measurement of the glutamate levels was adjusted for
age and IQ, the difference remained significant (p,0.002 after
adjustment for age; p,0.002 after adjustment for IQ). When the
measurement of the glutamine levels was adjusted for age and IQ,
the difference remained significant for IQ (p,0.0004), but became
even more conspicuous after adjustment for age (p,0.0001).
Using discriminant analysis with logistic regression that included
the four variables of age, IQ, and plasma glutamate and glutamine
levels, the correct classification rate was found to be 91%. The
sensitivity and specificity were 90% and 91%, respectively. The
parameter estimates in this logistic regression model are shown in
Table 3.
We then examined the correlations between plasma glutamate/
glutamine levels and autism-related symptoms of three separate
domains among individuals with HFA. There was no significant
correlation between the glutamate/glutamine levels and the three
subscores as assessed by the ADI-R.
Discussion
We found that the platelet-poor plasma level of glutamate in
children with HFA was significantly higher than that of normally
developing children, which supports the hyperglutamatergic
hypothesis of autism. In our previous study, we demonstrated an
increased level of glutamate in young adults (18–26 years) with
autism [17]. That finding, taken together with the results of the
current study, suggests the presence of elevated glutamate in the
plasma of autistic individuals early in life. Moreover, this elevation
appears to be sustained over a long period of time, i.e., into
adulthood. Thus, it appears likely that the plasma glutamate level
could serve as a long-term stable screening tool for autism.
In addition, we found that the plasma level of glutamine was
significantly lower in children with HFA than in the controls. This
finding was not anticipated prior to the study, and the difference
between the HFA and control groups was highly significant
(p,0.0004). Thus, it is very unlikely that this difference between
the two groups could be attributed to a chance finding. Of note in
this context are the identical results of a previous study by Aldred
et al. [20] showing reduced levels of glutamine together with
elevated levels of glutamate in the plasma of individuals with
Figure 1. Plasma Levels of Glutamate and Glutamine in Control Subjects and Individuals with HFA. Fig. 1-a: Glutamate Levels; Fig. 1-b:
Glutamine Levels. Plasma levels of glutamate and glutamine were determined using HPLC. Control subjects, N=22; individuals with HFA, N=23. Left
to right: t=3.77, df=43, p,0.002; t=24.55, df=43, p,0.0004. The plasma glutamate level was significantly higher (p,0.002), and the plasma
glutamine level was significantly lower (p,0.0004) in the HFA group than in the control group. When two autistic cases with extreme values were
eliminated from the glutamate data, the results changed only negligibly; p,0.002.
doi:10.1371/journal.pone.0025340.g001
Table 2. Clinical Characteristics of Control Subjects and
Individuals with HFA.
Control (n=22) HFA (n=23) p-value
Age (years) 12.262.4 (9–17) 13.562.5 (8–17) 0.081
Full-scale IQ 108.1614.6 99.6613.5 0.052
BMI 17.862.1 18.663.3 0.29
Creatinine (mg/dl) 0.5060.13 0.5360.13 0.33
ADI-R
Domain A score, social 18.365.2 (12–26)
Domain BV score,
communication
11.664.4 (3–21)
Domain C score, stereotype 5.162.8 (1–9)
BMI: body mass index.
ADIR: Autism Diagnostic Interview-Revised.
HFA: High-Functioning Autism.
Values are expressed as the mean 6 SD.
Two-tailed unpaired t-test.
doi:10.1371/journal.pone.0025340.t002
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more specifically, a direct comparison with the present study—is
hampered by methodological differences. In the study by Aldred et
al. [20], a smaller number of amino acids (n=17) was examined
compared with our study (n=25); a looser criterion for statistical
significance of p,0.05 was used (no account was taken of multiple
testing); controls were chosen from those who had been admitted
to a hospital due to physical problems and, thus, were more similar
to autistic subjects in terms of poor health; the age range was wider
and adults were included (4–29 years for the autism group); and
platelet-rich, instead of platelet-poor, plasma was used, which
rendered the present study using platelet-poor plasma advanta-
geous in terms of the serological investigation of autism, as
described above.
Due to the heterogeneity of autism [21], we attempted to recruit
and analyze a relatively homogeneous group. We therefore
restricted our study sample to the following: males, relatively
young subjects (to minimize the factors related to the illness
duration), only drug-naı ¨ve cases, and those individuals with a full-
scale IQ of higher than 70 (i.e., HFA). Further, the amount of
muscle mass in the body is important in examining glutamine and
glutamate levels, because the skeletal muscle accounts for a major
portion of glutamine synthesis. Failure to control for variation in
the amount of body muscle would lead to unreliable findings. In
this study, we assessed the plasma creatinine level, which reflects
the quantity of muscle mass, and we also included BMI in our
evaluation. We found no significant group differences in these
variables, suggesting that variation in the skeletal muscle mass was
unlikely to have confounded our results. However, we also
performed additional ANCOVA, in which we adjusted for plasma
creatinine levels and BMI. In these analyses, the significant
glutamate and glutamine findings remained unchanged (p,0.002
for all comparisons).
In this study, substantial differences between children with HFA
and healthy controls were represented by the high effect size for
glutamate and glutamine measures (above 1.0 for both).
Furthermore, using these two plasma measures, we successfully
discriminated between the autistic and control groups; the correct
classification rate was 91% with a sensitivity of 90% and a
specificity of 91%. Therefore, the present results suggest that early
assessment of the plasma levels of these two amino acids could be
used as a potential screening tool for HFA.
As aforementioned, excess glutamate in extracellular spaces is a
potent neurotoxin that leads to neuronal cell death. Perhaps as a
result of this, glutamate homeostasis is well maintained by several
cell specific elements, including membrane transporters and
enzymes that catalyze glutamate metabolism, in both extracellular
and intracellular spaces [27]. Glutamate concentrations in plasma
are 50–100 mM, whereas, in the whole brain, glutamate
concentrations are 10,000–12,000 mM, but they are only 0.5–
2 mM in extracellular fluids, indicating that glutamate concentra-
tions are overwhelmingly higher in intracellular spaces [28]. In this
concentration gradient, glutamate transporters (excitatory amino
acid transporters; EAATs) are thought to play a key role in the
periphery as well as in CNS [29]. In the brain capillary endothelial
cells, the EAATs exist exclusively in the abluminal membranes
and shift glutamate from the extracellular fluids to the endothelial
cells. Thus, the EAATs in the abluminal membranes of the blood
brain barrier (BBB) act as an active efflux pump for glutamate to
reduce the extracellular concentration of glutamate [30]. Further-
more, the EAATs also exist in neurons and astrocytes, where they
help to reduce the extracellular glutamate concentration. Recent-
ly, several lines of evidence derived from genetic studies have
shown the strong association between EAAT3 (also known as
SLC1A1, expressed in the CNS and periphery) and autism,
suggesting that the EAATs may, in fact, play a part in the
pathophysiology of autism [31,32,33]. Given that EAATs are
altered in the brains of subjects with autism, EAATs may be
involved in our finding of plasma glutamate abnormality in
autism.
In the cell body, glutamate is regulated by enzymes that catalyze
its degradation (e.g., glutamine synthetase [GS], an enzyme that
converts glutamate to glutamine) and enzymes that catalyze its
biosynthesis (e.g., glutaminase 1 [GLS1], an enzyme that
synthesizes glutamate from glutamine and is an isoform dominant
in the CNS; and glutamate dehydrogenase 1 [GDH1], an enzyme
that synthesizes glutamate from a-ketoglutarate and is an isoform
dominant in the brain). In the CNS, GS synthesizes glutamine
from glutamate following glial uptake of glutamate in the synaptic
cleft. Glutamine is transported back to presynaptic terminals and
converted to glutamate by GLS [27]. This multicellular enzymatic
process, termed the glutamate-glutamine cycle, is critical for
maintaining synaptic function and has been shown to be impaired
in various CNS disorders, including epilepsy, Parkinson’s disease,
Alzheimer’s disease, stroke and traumatic brain injury [34]. Since
it has been reported that peripheral glutamate/glutamine levels
are correlated with those of the CNS [12,13], our findings of
altered plasma levels of glutamate/glutamine are compatible with
evidence suggesting the relationship between a dysregulation of
glutamine/glutamate metabolism and increased levels of gliosis in
the brains of individuals with autism. An increase in gliosis, which
is characterized by enhanced activation of astrocytes and
microglia, has been observed in the brains of individuals with
autism [35,36]. Interestingly, Ortinski et al. have reported that
activated astrocytes downregulate the expression of glutamine
synthetase, whereby glutamate is converted into glutamine, which
in turn results in reduced glutamine coupled with elevated
glutamate [34]. In addition, glutaminase, another enzyme related
to glutamate/glutamine metabolism via its conversion of gluta-
mine into glutamate, has been shown to be upregulated in
activated microglia [37]. Thus, it is tempting to assume that the
process of gliosis generation may be related to the etiology of
autism, as mediated by activated astrocytes and/or activated
microglia, which may disturb the regulation of certain types of
enzymes and thereby alter the metabolism of glutamate/
glutamine. Taken together with previous findings, our results
demonstrating glutamate/glutamine abnormalities in the plasma
of individuals with autism may be indicative of a gliosis process in
the autistic brain.
The present results should be interpreted in the context of the
following limitations. Since the sample size was small, replication
with a larger sample will be needed to confirm our findings.
Table 3. Parameter Estimates in Discriminant Analysis with
Logistic Regression: Coefficients Based on the Logit Model.
Variables Coefficient 95%CI p-value
Age (years) 0.88 20.25–2.01 0.13
IQ 20.07 20.16–0.03 0.19
Glutamate 0.73 0.05–1.41 0.04
Glutamine 20.09 20.18–20.004 0.04
Constant 23.52 23.08–50.12 0.08
Discriminant analysis with logistic regression and four included variables: age,
IQ, and plasma glutamate and glutamine levels; correct classification rate, 91%.
doi:10.1371/journal.pone.0025340.t003
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d=1.13 for glutamate), hypothesized increases in the plasma levels
of glutamate were supported by the data, and multiple testing was
taken into account in the analyses. Thus, the conclusions of the
present study can be considered robust. However, to establish
plasma glutamate and glutamine levels as screening tools for a
diagnosis of autism, further studies using independent samples of
children are required. In this study, we investigated a relatively
homogeneous subpopulation of individuals with HFA—that is,
only drug-naı ¨ve, male children with a normal IQ. Thus, the
present findings cannot be generalized to the whole population of
persons with this disorder. Furthermore, although we focused on a
relatively young population of individuals (i.e., children) with HFA
in this study, it is of note that each individual received diagnosis
early in life and underwent the subsequent course of the disorder
for several years. Therefore, it is possible that our findings of
higher levels of plasma glutamate and lower levels of plasma
glutamine may be attributable to the duration of the condition
rather than its pathophysiological mechanism. Nevertheless, the
present study showing glutamatergic abnormalities in the periph-
eral blood of children with autism suggests that these children may
have a dysfunction of the brain glutamatergic system. These results
provide new insights into the pathophysiology of autism, which
may be particularly helpful for the development of novel
diagnostic strategies.
Materials and Methods
1. Participants
Twenty-three male children and adolescents with autism who
were drug-naı ¨ve (age=13.562.5 years [mean 6 S.D.]; range=8–
17), and 22 normally developed male controls (age=12.262.4
years; range=9–17) were recruited for this study (Table 2). The
recruitment of persons with autism spectrum disorders was assisted
by a nonprofit organization, the Asperger Society of Japan. All
participants in both the autism and control groups were Japanese.
Enrolled participants with autism were initially assessed by trained
child psychiatrists according to the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revision
(DSM-IV-TR) [38]. Further, diagnostic evaluation was based on a
structured interview with a parent, using the Autism Diagnostic
Interview-Revised (ADI-R) [39]. The Wechsler Adult Intelligence
Scale, third edition (WAIS-III), or the Wechsler Intelligence Scale
for Children, third edition (WISC-III), was employed to evaluate
intelligence, and all participants, including those with autism, were
confirmed to have a full scale IQ score above 70; i.e., the autism
group included only individuals with HFA.
Normally developed children (control group) were recruited
through advertisements in local newspapers. All control partici-
pants underwent a comprehensive assessment of their medical
history to exclude those with neurological or other medical
disorders. The Structured Clinical Interview for the DSM-IV
Axis-I Diagnoses (SCID-I) was also conducted to screen all
participants for any past or present mental illness. Neither
neuropsychiatric disorders other than autism nor medical
conditions (e.g., epilepsy) that could potentially affect glutamater-
gic metabolism were found to be present in the 23 participants
with HFA. None of the control participants recruited was
diagnosed with any neuropsychiatric condition.
All participants and parents were given a complete description
of the study, and written informed consent was obtained from all
of them prior to enrollment in the study. Approval for the present
study was acquired from the ethics committee of the Hamamatsu
University School of Medicine.
2. Assessment of autistic symptoms
The ADI-R described above was used to provide information
on the autism-related symptoms in three separate domains.
Domain A quantifies impairment of social interaction (score
range: 0–32); domain B evaluates impairment of communication
(score range: 0–26); and domain C assesses restricted, repetitive,
and stereotyped patterns of behavior and interests (score range: 0–
16).
3. Blood collection procedure
Plasma samples of the participants in both the HFA and control
groups were all collected between 11:00 and 12:00 a.m. before
lunch to minimize potential effects of food intake. Blood was taken
into 7-ml blood collection tubes containing EDTA-2Na, and
samples were immediately centrifuged at 10006g for 15 minutes
to obtain platelet-poor plasma. The plasma was decanted,
aliquoted to avoid multiple freeze-thaw cycles and stored for up
to 4 months at 280uC until analysis.
4. Amino acid measurement
The plasma samples obtained were homogenized in 1.5 volumes
of 5% 5-sulfosalicylic acid (final concentration: 2.0%). The
homogenates were centrifuged immediately at 12000 rpm 4uC
for 10 minutes to remove precipitated protein. The supernatants
were collected and used for amino acid measurement. The
concentration of amino acids in the plasma samples was measured
using an automatic HPLC system (L-8500A; Hitachi High-
Technologies Corporation, Tokyo, Japan). Briefly, amino acids,
separated by cation-exchange chromatography, were detected
spectrophotometrically after postcolumn reaction with ninhydrin
reagent. Although we examined 41 amino acids, 16 of them were
undetectable in the plasma using HPLC. Consequently, the 25
amino acids examined were as follows: alanine, a-aminobutyric
acid, arginine, asparagine, citrulline, cystine, glutamate, gluta-
mine, glycine, histidine, hydroxyproline, isoleucine, leucine, lysine,
methionine, ornithine, phenylalanine, proline, serine, taurine,
threonine, tryptophan, tyrosine, urea, and valine (see Table 1).
The 16 amino acids that were unmeasurable by HPLC in either
the autistic or control group were as follows: ß-alanine, a-
aminoadipic acid, c-aminobutyric acid, c-amino ß-hydroxybutyric
acid, ß-amino-iso-butyric acid, anserine, aspartic acid, carnosine,
cystathionine, homocystine, hydroxylysine, 1-methylhistidine, 3-
methylhistidine, monoethanolamine, phosphoethanolamine, and
sarcosine. The plasma creatinine level, which reflects the quantity
of muscle mass, was also measured using the creatininase-
creatinase-sarcosine oxidase-POD method [40]. This assessment
was made because the skeletal muscle accounts for a major portion
of glutamine synthesis in the human body; thus, varying amounts
of muscle mass in individuals could have a confounding effect,
especially when amino acid levels of glutamate and glutamine are
evaluated.
5. Statistical analysis
All data are presented as the mean 6 standard deviation (S.D.),
unless otherwise indicated. The data were analyzed using the
unpaired t-test due to the approximate normal distribution of the
data. The relationships between amino acid levels and clinical
variables among individuals with autism were evaluated by
Pearson’s correlation coefficients. As we examined each of the
25 amino acids levels separately, a p-value of less than 0.002 was
considered to be statistically significant, according to the
Bonferroni correction [41]. Analysis of covariance (ANCOVA)
Plasma Glutamatergic Changes in Autistic Children
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(Cohen’s d) for variables with a significant group difference.
Then, we investigated whether amino acids could serve as a
diagnostic tool using a discriminant function analysis. In the
logistic regression analysis, we calculated the correct classification
rate. All analyses were performed with Stata/SE 10.0 software for
windows (Stata Corp., College Station, TX).
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